Tradename | Company | Number | Date | Products |
---|---|---|---|---|
NOVANTRONE | EMD Serono | N-019297 DISCN | 1987-12-23 | 3 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
mitoxantrone | ANDA | 2025-01-20 |
Code | Description |
---|---|
J9293 | Injection, mitoxantrone hydrochloride, per 5 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | — | — | — | 1 | — | 1 |
Nervous system diseases | D009422 | — | G00-G99 | — | — | — | 1 | — | 1 |
Autoimmune diseases of the nervous system | D020274 | — | — | — | — | — | 1 | — | 1 |
Neuromyelitis optica | D009471 | EFO_0004256 | G36.0 | — | — | — | 1 | — | 1 |
Transverse myelitis | D009188 | — | G37.3 | — | — | — | 1 | — | 1 |
Myelitis | D009187 | — | G04.91 | — | — | — | 1 | — | 1 |
Cns demyelinating autoimmune diseases | D020278 | EFO_1000870 | G37 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | — | — | 1 | 1 |
Sclerosis | D012598 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Mitoxantrone |
INN | mitoxantrone |
Description | Mitoxantrone is a dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8. It has a role as an antineoplastic agent and an analgesic. |
Classification | Small molecule |
Drug class | antineoplastics, anthraquinone derivatives |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21 |
PDB | — |
CAS-ID | 65271-80-9 |
RxCUI | — |
ChEMBL ID | CHEMBL58 |
ChEBI ID | 50729 |
PubChem CID | 4212 |
DrugBank | DB01204 |
UNII ID | BZ114NVM5P (ChemIDplus, GSRS) |